NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 49 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $600,665 | -38.3% | 231,917 | -2.8% | 0.00% | -100.0% |
Q1 2023 | $973,145 | -20.5% | 238,516 | -2.2% | 0.00% | 0.0% |
Q4 2022 | $1,224,152 | -64.4% | 243,855 | -7.2% | 0.00% | -50.0% |
Q3 2022 | $3,439,000 | +1.6% | 262,851 | -0.4% | 0.00% | 0.0% |
Q2 2022 | $3,384,000 | +29.1% | 263,912 | +53.5% | 0.00% | +100.0% |
Q1 2022 | $2,622,000 | -12.0% | 171,894 | +2.2% | 0.00% | 0.0% |
Q4 2021 | $2,979,000 | -19.6% | 168,244 | -4.5% | 0.00% | -50.0% |
Q3 2021 | $3,705,000 | +22.9% | 176,235 | +15.3% | 0.00% | +100.0% |
Q2 2021 | $3,014,000 | -60.8% | 152,854 | -42.3% | 0.00% | -75.0% |
Q1 2021 | $7,694,000 | +1327.5% | 264,702 | +1389.1% | 0.00% | – |
Q4 2020 | $539,000 | +160.4% | 17,776 | +36.8% | 0.00% | – |
Q3 2020 | $207,000 | -11.5% | 12,990 | +9.6% | 0.00% | – |
Q2 2020 | $234,000 | +93.4% | 11,854 | +21.0% | 0.00% | – |
Q1 2020 | $121,000 | -26.7% | 9,797 | +9.1% | 0.00% | – |
Q4 2019 | $165,000 | +534.6% | 8,978 | +343.8% | 0.00% | – |
Q3 2019 | $26,000 | -46.9% | 2,023 | -40.3% | 0.00% | – |
Q2 2019 | $49,000 | – | 3,389 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |